Undisclosed Group Seeks to Discredit Genfit’s Clinical Drug Candidate GFT505

It has come to the attention of Genfit, a leading biotech company listed on Alternext (NYSE Euronext - Paris), that an undisclosed group of so-called “well known scientific experts” have issued a press release, via a news wire, purporting to put into question the effectiveness of Genfit’s main clinical drug candidate GFT 505.

Not only is this press release issued by its author(s) in a manner contrary to basic scientific methodology, i.e. under the shroud of anonymity, but its content sets out what Genfit believe to be erroneous and even blatantly false statements and conclusions the purpose of which is evidently aimed at misleading the industry and the market.

This undisclosed group has evidently turned to a drastic objective of discrediting the drugs under development by Genfit.

Genfit (Paris:ALGFT) has discovered the identity of the promoter of said press release and will take all actions necessary, including before the courts, to abate such grave behaviour. (www.genfit.com)